Skip to main content

Table 4 Annual per capita costs of chemotherapy and immunotherapy for metastatic melanoma

From: Hospitalisation costs of metastatic melanoma in France; the MELISSA study (MELanoma In hoSpital coSts Assessment)

  Patients Stays Annual per capita cost
National tariff ENCC Adjusted ENCC
Ipilimumab
 Pre-progression 55 165 € 64,017 € 3949 € 63,895
 Acquisition (0.8%) (0.6%) € 62,215 NA € 62,215
 Administration    € 1802 NA € 1680
 Post-progression 348 949 € 43,735 € 2529 € 43,657
 Acquisition (6.9%) (2.6%) € 42,530 NA € 42,530
 Administration    € 1205 NA € 1127
Fotemustine
 Pre-progression 139 541 € 5194 € 5937 € 5044
 Acquisition (1.9%) (2.0%) € 2372 NA € 2372
 Administration    € 2822 NA € 2672
 Post-progression 969 3192 € 3432 € 3603 € 3337
 Acquisition (19.1%) (8.7%) € 1696 NA € 1696
 Administration    € 1736 NA € 1641
Other chemotherapies a
 Pre-progression 1475(20.1%) 4845(18.0%) € 3378 € 6205 € 3252
 Post-progression 2052(40.5%) 10,214(28.0%) € 2736 € 5292 € 2601
  1. NA not available
  2. aSince other chemotherapies are not included in the FICHCOMP list, drug acquisition and administration costs are consolidated for all three valuation methods. ENCC: Études Nationales de Coûts à Méthodologie Commune